- Home
- ISRG vs GILD Comparison
ISRG vs GILD Comparison
Compare ISRG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRG
- GILD
- Stock Information
- Founded
- ISRG 1995
- GILD 1987
- Country
- ISRG United States
- GILD United States
- Employees
- ISRG N/A
- GILD N/A
- Industry
- ISRG Medical/Dental Instruments
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRG Health Care
- GILD Health Care
- Exchange
- ISRG Nasdaq
- GILD Nasdaq
- Market Cap
- ISRG 154.0B
- GILD 145.4B
- IPO Year
- ISRG 2000
- GILD 1992
- Fundamental
- Price
- ISRG $457.93
- GILD $123.18
- Analyst Decision
- ISRG Buy
- GILD Buy
- Analyst Count
- ISRG 16
- GILD 23
- Target Price
- ISRG $588.07
- GILD $116.82
- AVG Volume (30 Days)
- ISRG 2.2M
- GILD 7.9M
- Earning Date
- ISRG 10-21-2025
- GILD 10-30-2025
- Dividend Yield
- ISRG N/A
- GILD 2.57%
- EPS Growth
- ISRG 23.20
- GILD 496.80
- EPS
- ISRG 7.17
- GILD 5.01
- Revenue
- ISRG $9,145,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- ISRG $19.57
- GILD $2.08
- Revenue Next Year
- ISRG $14.45
- GILD $3.96
- P/E Ratio
- ISRG $62.23
- GILD $24.51
- Revenue Growth
- ISRG 20.77
- GILD 3.81
- 52 Week Low
- ISRG $425.00
- GILD $85.60
- 52 Week High
- ISRG $616.00
- GILD $124.11
- Technical
- Relative Strength Index (RSI)
- ISRG 55.71
- GILD 71.52
- Support Level
- ISRG $427.84
- GILD $115.80
- Resistance Level
- ISRG $440.82
- GILD $124.11
- Average True Range (ATR)
- ISRG 11.16
- GILD 3.12
- MACD
- ISRG 2.29
- GILD 0.95
- Stochastic Oscillator
- ISRG 83.31
- GILD 95.34
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).